NeoGenomics (NEO) Earning Somewhat Favorable News Coverage, Report Finds

News coverage about NeoGenomics (NASDAQ:NEO) has trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. NeoGenomics earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.0615649973394 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

These are some of the news headlines that may have impacted Accern Sentiment’s rankings:

How to Become a New Pot Stock Millionaire

Several equities analysts have commented on NEO shares. Zacks Investment Research upgraded shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Thursday, March 1st. BidaskClub downgraded shares of NeoGenomics from a “hold” rating to a “sell” rating in a research note on Thursday, January 18th. Scotiabank set a $22.00 price target on shares of NeoGenomics and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Canaccord Genuity boosted their price target on shares of NeoGenomics from $23.00 to $24.00 in a research note on Tuesday, March 13th. Finally, CIBC set a $19.00 price target on shares of NeoGenomics and gave the stock a “neutral” rating in a research note on Wednesday, January 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $17.29.

Shares of NeoGenomics stock traded up $0.01 during trading on Friday, hitting $8.11. 188,591 shares of the stock were exchanged, compared to its average volume of 260,866. The stock has a market cap of $652.11, a P/E ratio of 135.17, a price-to-earnings-growth ratio of 4.50 and a beta of 0.42. NeoGenomics has a 12-month low of $7.08 and a 12-month high of $11.63. The company has a current ratio of 2.42, a quick ratio of 2.21 and a debt-to-equity ratio of 0.56.

NeoGenomics (NASDAQ:NEO) last released its quarterly earnings data on Wednesday, February 21st. The medical research company reported $0.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.02. The business had revenue of $67.79 million during the quarter, compared to analysts’ expectations of $66.32 million. NeoGenomics had a negative net margin of 1.37% and a positive return on equity of 4.34%. The company’s revenue for the quarter was up 12.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.05 EPS. sell-side analysts forecast that NeoGenomics will post 0.09 earnings per share for the current fiscal year.

WARNING: “NeoGenomics (NEO) Earning Somewhat Favorable News Coverage, Report Finds” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another publication, it was copied illegally and reposted in violation of U.S. and international trademark & copyright legislation. The original version of this piece can be read at https://www.tickerreport.com/banking-finance/3338181/neogenomics-neo-earning-somewhat-favorable-news-coverage-report-finds.html.

About NeoGenomics

NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

8,380 Shares in American Campus Communities  Acquired by LPL Financial LLC
8,380 Shares in American Campus Communities Acquired by LPL Financial LLC
Intrexon  Shares Sold by LPL Financial LLC
Intrexon Shares Sold by LPL Financial LLC
LPL Financial LLC Buys Shares of 7,295 Donaldson
LPL Financial LLC Buys Shares of 7,295 Donaldson
LPL Financial LLC Acquires New Stake in ProShares MSCI Europe Dividend Growers ETF
LPL Financial LLC Acquires New Stake in ProShares MSCI Europe Dividend Growers ETF
Longer Investments Inc. Has $2.55 Million Position in Microsoft Co.
Longer Investments Inc. Has $2.55 Million Position in Microsoft Co.
Apple  Shares Bought by Lenox Wealth Management Inc.
Apple Shares Bought by Lenox Wealth Management Inc.


© 2006-2018 Ticker Report. Google+.